Insider trade

Martine A Rothblatt, CEO at United Therapeutics, sold ~$604K of United Therapeutics shares.

~$604K
Approx. value · 1,345 sh @ $449.44
130
Holds after · shares reported
Traded
Nov 6, 2025
Filed
Nov 8, 2025

What stands out in this filing

  • The sale was 91.2% of the shares this insider held before it; the filing reports 130 shares afterwards.
  • 1,345 shares at an average of $449.44 each, as reported on the form.
  • Footnote references a pre-arranged trading plan (Rule 10b5-1).

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 8, 2025Insider · 1 personInsiders: 11 sales (~$2.0M)
  2. Sep 9, 2025Insider · 3 peopleInsiders: 5 sales (~$8.0M)
  3. Sep 10, 2025Insider · 2 peopleInsiders: 3 sales (~$3.4M)
  4. Sep 11, 2025InsiderCEO sold ~$1.59M of UTHR shares in the open market
  5. Sep 12, 2025Insider · 1 personInsiders: 3 sales (~$1.6M)
  6. Sep 15, 2025Insider · 2 peopleInsiders: 16 sales (~$10.6M)
  7. Sep 16, 2025Insider · 1 personInsiders: 2 sales (~$1.6M)
  8. Sep 17, 2025Insider · 1 personInsiders: 2 sales (~$1.6M)
  9. Sep 18, 2025Insider · 2 peopleInsiders: 9 sales (~$6.1M)
  10. Sep 19, 2025Insider · 2 peopleInsiders: 2 sales (~$2.4M)
  11. Sep 22, 2025Insider · 2 peopleInsiders: 4 sales (~$11.0M)
  12. Sep 23, 2025Insider · 1 personInsiders: 2 sales (~$1.7M)
  13. Sep 24, 2025Insider · 2 peopleInsiders: 3 sales (~$2.2M)
  14. Sep 25, 2025Insider · 1 personInsiders: 3 sales (~$1.7M)
  15. Sep 26, 2025Insider · 1 personInsiders: 2 sales (~$1.7M)
  16. Oct 3, 2025Insider · 1 personInsiders: 3 sales (~$1.8M)
  17. Oct 6, 2025Insider · 2 peopleInsiders: 9 sales (~$8.7M)
  18. Oct 29, 2025Company filing · Form 8-K · ResultsReported its results

What came next

  1. Jan 21, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On January 21, 2026, the Board of Directors (the “ Board ”) of United Therapeutics Corporation (the “ Company ”), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Kevin J. Tracey, M.D., to serve as a member of the Board.”
  2. Feb 25, 2026Company filing · Form 8-K · ResultsReported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for United Therapeutics

For United Therapeutics, OQRO holds 907 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its UTHR page.

Other recent filings by Martine A Rothblatt, Chairperson & CEO

The full history of Martine A Rothblatt, Chairperson & CEO is on the profile page.

How this filing works

Explore the data

Common questions

Which United Therapeutics (UTHR) insider traded, and how much?

Martine A Rothblatt, CEO at United Therapeutics, sold ~$604K of United Therapeutics shares. 1,345 shares at $449.44.

When did it happen, and when was it made public?

Traded: Nov 6, 2025. Filed: Nov 8, 2025. That is 2 days between the two dates.

What stands out in this filing?

The sale was 91.2% of the shares this insider held before it; the filing reports 130 shares afterwards. 1,345 shares at an average of $449.44 each, as reported on the form. Footnote references a pre-arranged trading plan (Rule 10b5-1).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about United Therapeutics recently?

For United Therapeutics, OQRO holds 907 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the UTHR page.

Does this mean UTHR stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at United Therapeutics

Everything OQRO holds on this company is on its UTHR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data